Last updated: February 4, 2026
Case Overview
Janssen Biotech, Inc. filed a patent infringement lawsuit against Celltrion Healthcare Co., Ltd. in the District of Massachusetts. The case number is 1:17-cv-11008. The dispute revolves around biosimilar versions of Janssen’s Remicade (infliximab). Janssen alleges that Celltrion’s proposed biosimilar infringes on patents covering Remicade’s composition and method of use.
Chronology and Key Events
- Filing Date: December 20, 2017
- Claims: Patent infringement under 35 U.S.C. § 271.
- Patents Asserted: Several patents, primarily relating to the composition of matter and methods of treatment involving infliximab.
- Legal Motions: Celltrion filed motions to dismiss and for summary judgment, asserting invalidity of patents based on prior art and obviousness.
- Court Rulings:
- As of the latest update, the court granted summary judgment in favor of Janssen on certain patent claims, upholding their validity.
- The court denied Celltrion’s motions to dismiss, allowing infringement claims to proceed.
- Settlement/Resolution: The case remains active as of the last docket entry, with ongoing discovery.
Patent and Product Details
| Patent Number |
Issue Date |
Claim Focus |
Status |
| US 8,567,828 |
October 29, 2013 |
Composition of infliximab with specific glycosylation |
Validated |
| US 9,829,241 |
November 28, 2017 |
Methods of producing infliximab |
Validated |
Celltrion’s biosimilar candidate, known as CT-P13, aims to replicate Remicade’s structure, with disputes centered on whether it infringes the composition patents or relies on exempted manufacturing steps.
Legal Issues
- Patent Validity: Patent challenges based on prior art disclosures, obviousness, and enablement.
- Infringement: Whether Celltrion’s biosimilar product infringes on Janssen’s patents via composition or process.
- Regulatory Competition: Celltrion seeks FDA approval through a biosimilar pathway, raising issues about patent term extensions and market entry strategies.
Strategic and Market Implications
- The case influences biosimilar patent strategies for Janssen and other biologics companies.
- A favorable outcome for Janssen preserves market exclusivity and prevents biosimilar entry.
- The litigation exemplifies the ongoing patent-protection battles in the rapidly growing biosimilar sector.
Key Legal Trends
- Patent Evergreening: Janssen’s patents focus on formulation and manufacturing methods to extend exclusivity.
- Biosimilar Patent Challenges: Celltrion’s defenses leverage prior art and obviousness, common in biosimilar patent litigation.
- Regulatory Interplay: FDA approval pathways for biosimilars are intertwined with litigation, affecting market timelines.
Current Status
The case proceeds through discovery and pre-trial motions. No final judgment or settlement has been publicly reported. With biosimilar approvals imminent or filed, further court activity could influence market entry.
Key Takeaways
- Janssen’s patent protection for infliximab remains partially upheld, restricting biosimilar market entry.
- Celltrion’s legal strategies focus on patent invalidity and non-infringement defenses.
- Litigation timing coincides with biosimilar regulatory approval processes, impacting commercial launches.
- Patent disputes in this sector underscore the strategic importance of patent lifecycle management.
- Ongoing court decisions will shape the legal environment for biosimilar development and patent enforcement.
FAQs
1. What is the primary legal issue in Janssen v. Celltrion?
The case centers on whether Celltrion’s biosimilar infringes Janssen’s patents covering infliximab and whether those patents are valid.
2. How long are patent disputes like this expected to last?
Biologics patent cases often extend over multiple years due to complex validity and infringement questions, with some cases lasting 3-5 years or longer.
3. What is the impact of this case on biosimilar market entry?
A ruling favoring Janssen could delay or prevent Celltrion’s biosimilar launch, prolonging market exclusivity for Remicade.
4. How do patent challenges in biosimilars differ from small-molecule drugs?
Biosimilar patents are more complex due to biological manufacturing processes, requiring detailed analysis of composition and production methods.
5. Can courts block biosimilar approval?
Yes, courts can issue injunctions or rulings that prevent biosimilar marketing if patents are upheld, but regulatory approvals generally proceed unless patent issues are resolved.
References
[1] Federal Court Docket: Janssen Biotech, Inc. v. Celltrion Healthcare Co., Ltd., No. 1:17-cv-11008 (MA D. Ct.)
[2] FDA Biosimilar Approval Pathway: 21 CFR Part 607
[3] Patent Documents: US 8,567,828; US 9,829,241
